Important note: Information in this article was accurate in 2005. The state of the art may have changed since the publication date.
![]()
Reuters NewMedia - January 10, 2005
Patricia Reaney
They found a crucial difference between a gene in humans and one in rhesus monkeys that blocks infection of the virus in the animals -- a finding that offers new insights into the origins of AIDS and gene therapy.
Had the gene been the same in humans, scientists at the National Institute of Medical Research in London believe, there may not have been the AIDS epidemic that now affects 40 million people worldwide.
"If it had recognized HIV, we probably would never have had AIDS. I believe it is a key change," said Dr Jonathan Stoye, head of virology at the institute.
Scientists had been aware that it was much more difficult to infect monkey cells with HIV than human cells in laboratory experiments, which suggested there was something different in the animal cells that blocked infection.
A gene called Trim 5 alpha was later found to be the reason why. In monkeys, but not in humans, it stops the virus from replicating.
Stoye and his team studied differences in the gene products of the monkey and human Trim 5 alpha genes. They pinpointed one specific change in a protein that was important in blocking HIV. By substituting a human protein with a monkey-derived protein they found they could make the human cells resistant to HIV.
"The discovery has significant implications for the development of effective gene therapy to combat AIDS," Stoye, who reported the findings in the journal Current Biology, told Reuters.
He and his team believe introducing the gene carrying that single change back into human cells would make those cells resistant to HIV infection.
Gene therapy is an experimental technique which introduces genetic material into cells to fight disease. The technique has been used for Parkinson's disease and in trials for illnesses such as cystic fibrosis and cancer.
Two French boys with severe immune deficiency were cured with gene therapy but they later developed leukemia.
"If you have HIV this might be a form of therapy to prevent progression to AIDS. What we are suggesting one might try doing is to purify HIV negative cells out of a patient who has been infected, introduce the gene with this one modification and then put them back into people," said Stoye.
The resistant cells might be sufficient to prevent the progression to AIDS, he added.
But Stoye stressed that more laboratory research, followed by animal tests and human trials will be needed.
"If this were the equivalent of adding a drug with a new target to the repertoire of drugs that we have for the treatment of AIDS, I think it would be of value."
050110
RE050121
Copyright © 2005 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .